Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug distribution in renal failure

M Gibaldi

    The American Journal of Medicine
    |April 1, 1977
    PubMed
    Summary

    Renal disease can alter drug pharmacokinetics by reducing plasma protein binding, affecting drug distribution and clearance. However, daily doses of non-renally eliminated drugs may not need adjustment in patients with kidney disease.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Effect of plasma protein and tissue binding on the time course of drug concentration in plasma.

    Journal of pharmacokinetics and biopharmaceutics·2010
    Same author

    The pharmacokinetics of penamecillin.

    British journal of pharmacology and chemotherapy·2008
    Same author

    Vaccination updates.

    The Western journal of medicine·2000
    Same author

    Are phytoestrogens a "natural alternative" to estrogen replacement therapy?

    The Western journal of medicine·2000
    Same author

    Regulating angiogenesis: a new therapeutic strategy.

    Journal of clinical pharmacology·1998
    Same author

    Prevention and treatment of stroke: where do we stand?

    Journal of clinical pharmacology·1998

    Area of Science:

    • Pharmacology
    • Nephrology
    • Drug Metabolism

    Background:

    • Renal disease commonly impairs plasma protein binding of drugs.
    • This impairment can alter drug distribution and clearance, impacting overall pharmacokinetics.
    • Kidney dysfunction influences drugs eliminated via biotransformation, not just renal excretion.

    Purpose of the Study:

    • To investigate the pharmacokinetic implications of renal disease on drug disposition.
    • To assess the impact of impaired protein binding on drug concentrations in patients with renal impairment.
    • To provide guidance on drug dosing strategies in patients with kidney disease.

    Main Methods:

    • Review of existing literature on drug protein binding in renal disease.
    • Analysis of pharmacokinetic principles related to drug distribution and clearance.
    • Comparison of total and free drug concentrations in patients with and without renal disease.

    Main Results:

    • Renal disease leads to reduced plasma protein binding, increasing apparent volume of distribution and clearance.
    • Drugs eliminated by nonrenal mechanisms may achieve lower steady-state total plasma concentrations in renal disease.
    • Free (unbound) drug concentrations are likely similar in patients with and without renal disease, assuming no liver disease.

    Conclusions:

    • The usual daily dose of a drug eliminated by nonrenal mechanisms may not require alteration in patients with renal disease.
    • Divided dosing of such drugs is recommended to mitigate potential adverse effects.
    • Understanding these pharmacokinetic changes is crucial for safe and effective drug therapy in renal impairment.

    Related Experiment Videos